Around 1,700 Jan Dhan accounts under scanner in UP for suspicious deposits ahead of elections

New Delhi, Jun 25: After the Drug Controller General of India (DCGI) given its approval to manufacture and market the generic version of COVID-19 drug Remdesivir, COVIFOR, Hyderabad-based drugmaker Hetero Limited has delivered the first set of 20,000 vials in two equal lots of 10,000 each across 5 states.

The first batch, which is being marketed under the brand name of COVIFOR, was delivered to Maharashtra, Delhi, Gujarat Tamil Nadu and Hyderabad. Hetero has set a target to produce one lakh vials of the drug in two-three weeks.

The other lot would be supplied to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Cochin, Trivandrum and Goa within a week to meet the emergency requirements.

Managing director of Hetero Healthcare M Srinivasa Reddy said “the launch of Covifor in the country is a milestone in addressing public health emergencies. Through Covifor, we hope to reduce the treatment time of a patient in a hospital thereby reducing the increasing pressure on the medical infrastructure overburdened ue to accelerating COVID-19 infection rates," he said as reported by news agency.

"We are closely working with the government and the medical community to make Covifor quickly accessible to both public and private healthcare settings across the country”, Reddy said.

Covifor is a generic brand of Remdesivir which is used for the treatment of COVID-19 in adults and children hospitalised with strong symptoms of the disease. The Health Ministry had, on June 13, recommended the use of anti-viral drug Remdesivir in moderate stage of COVID-19.

Dr Reddys Laboratories and Hetero are among others which have separately entered into non-exclusive licensing agreements with the original drug-maker Gilead Sciences Inc to register, make and sell the investigational drug Remdesivir in India and other countries.

Remdesivir would be made in the company's formulation facility in Hyderabad, which has been approved by global regulatory authorities such as US Food and Drug Administration (USFDA) and EU, among others, Hetero had earlier said.

The treatment first showed improvement in trials on coronavirus patients and was approved for emergency use in severely ill patients in the United States and South Korea.

New Delhi, Jun 10: Delhi recorded 1,366 fresh cases of COVID-19 on Tuesday, taking the tally to 31,309, while the death toll mounted to 905, authorities said on Wednesday.

According to a health bulletin issued by the Delhi government's health department, there are 18,543 active cases, while 11,861 patients have either recovered, been discharged or migrated.

No health bulletin was issued on Tuesday.

Aligarh, Jan 14: Uttar Pradesh Minister Raghuraj Singh has courted a major controversy after he said that people who raise slogans against Prime Minster Narendra Modi and Uttar Pradesh Chief Minister Yogi Adityanath "would be buried alive".

The minister said this on Sunday while addressing a rally in Aligarh to muster support for the Citizenship Amendment Act (CAA) 2019.

"If you raise slogans against Prime Minister Narendra Modi or Chief Minister Yogi Adityanath, I will bury you alive," he threatened.

He was apparently referring to protests held by students of Aligarh Muslim University against the CAA during which they allegedly raised slogans against the Prime Minister and the chief minister.

The minister further said: "These one per cent people are opposing the CAA. They stay in India, eat up our taxes and then raise 'murdabad' slogans against the leaders. This country belongs to people of all faiths, but slogan shouting against the Prime Minister or chief minister is unacceptable."

He also launched an attack on India's first Prime Minister Jawaharlal Nehru. "What was Nehru's caste? He did not have a 'khaandan'," he claimed.

Raghuraj Singh is minister of state in the labour ministry in Uttar Pradesh.